Home > Haematology > EHA 2019 > Myeloid Malignancies > Gilteritinib prolongs overall survival in patients with FLT3-mutated relapsed/refractory AML

Gilteritinib prolongs overall survival in patients with FLT3-mutated relapsed/refractory AML

Expert
Dr Alexander Perl, University of Pennsylvania, USA
Conference
EHA 2019
Trial
Phase 3, ADMIRAL

Dr Alexander Perl (University of Pennsylvania, USA) presented the data from the phase 3 ADMIRAL trial of gilteritinib, a selective FLT3 inhibitor, for relapsed or refractory (R/R) acute myeloid leukaemia (AML). Patients were randomised 2:1 to receive either gilteritinib or one of 4 standard salvage chemotherapy treatments. The investigators report favourable outcomes of gilteritinib observed in this trial with increased complete response rate and improved overall survival for R/R AML [1].

FLT3 mutations (FLT3MUT+) occur in approximately 30% of patients with AML and are often associated with poor survival. Results from the ADMIRAL trial show the median overall survival for R/R FLT3MUT+ AML patients who received gilteritinib was 9.3 months vs 5.6 months for patients who received salvage chemotherapy (HR 0.637; 95% CI 0.490-0.830; P=0.007); 1-year survival rates were 37% for patie...



please login to read the entire article:


You need to register to read the entire article, please do so now.





Posted on